Takeda's profit forecast turns positive on successful Shire onboarding

4 February 2020

Japanese drugmaker Takeda (TYO: 4502) closed 1% up after Tuesday’s Tokyo trading.

The firm had that morning presented its latest financial results, which for Takeda are for its third quarter of fiscal year 2019/20, as the company’s fiscal year runs from April to March.

Revenue for the quarter was 2.52 trillion yen ($23 billion), with the 83% rise on the same period a year ago coming as a result of Takeda’s $62 billion acquisition of the rare diseases drugmaker, Shire. On a pro-forma basis, making a comparison with the combination of the two companies’ revenue, sales were down 1.2%, though this is expected to be flat by the forthcoming quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK